IRIS
Criscitiello, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.980
AS - Asia 949
EU - Europa 353
Continente sconosciuto - Info sul continente non disponibili 207
SA - Sud America 180
AF - Africa 39
OC - Oceania 4
Totale 3.712
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.831
SG - Singapore 313
CN - Cina 257
IT - Italia 164
BR - Brasile 123
VN - Vietnam 115
CA - Canada 58
IN - India 54
HK - Hong Kong 38
GB - Regno Unito 37
FR - Francia 35
BD - Bangladesh 34
MX - Messico 25
AR - Argentina 23
IQ - Iraq 19
SA - Arabia Saudita 18
DE - Germania 17
TR - Turchia 17
CR - Costa Rica 16
ES - Italia 14
ID - Indonesia 13
PL - Polonia 12
PK - Pakistan 11
RU - Federazione Russa 11
JM - Giamaica 10
CL - Cile 9
DZ - Algeria 9
EC - Ecuador 9
IE - Irlanda 8
MY - Malesia 8
PH - Filippine 8
UA - Ucraina 8
ZA - Sudafrica 8
FI - Finlandia 7
SV - El Salvador 7
JP - Giappone 6
MA - Marocco 6
PT - Portogallo 6
TT - Trinidad e Tobago 6
CO - Colombia 5
EG - Egitto 5
GT - Guatemala 5
NL - Olanda 5
TH - Thailandia 5
VE - Venezuela 5
AU - Australia 4
BE - Belgio 4
DO - Repubblica Dominicana 4
IL - Israele 4
PE - Perù 4
SE - Svezia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BZ - Belize 3
CZ - Repubblica Ceca 3
JO - Giordania 3
PA - Panama 3
RO - Romania 3
SN - Senegal 3
UZ - Uzbekistan 3
AT - Austria 2
BB - Barbados 2
CH - Svizzera 2
ET - Etiopia 2
GR - Grecia 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PR - Porto Rico 2
AG - Antigua e Barbuda 1
AL - Albania 1
BG - Bulgaria 1
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
EE - Estonia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MQ - Martinica 1
MW - Malawi 1
MZ - Mozambico 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
Totale 3.505
Salva come PNG Salva come JPEG
Città #
Council Bluffs 217
Santa Clara 127
Singapore 102
Beijing 94
San Jose 84
Ashburn 56
Phoenix 55
Los Angeles 37
Hong Kong 36
Milan 35
Ho Chi Minh City 32
New York 28
Rome 22
Dallas 21
Hanoi 21
Buffalo 19
Atlanta 13
Princeton 13
Seattle 13
The Dalles 13
Assago 12
Houston 12
Mexico City 12
San José 12
São Paulo 12
Brooklyn 11
North Bergen 11
Abbeville 10
Da Nang 10
Orem 10
Cincinnati 9
Hillsboro 9
Lorton 9
Naples 9
Queens 9
Shanghai 9
Auburn 8
Montreal 8
Newark 8
Philadelphia 8
Richmond 8
Chicago 7
Frankfurt am Main 7
Pittsburgh 7
San Antonio 7
Boardman 6
Columbus 6
Dammam 6
Geneva 6
Helsinki 6
Jacksonville 6
London 6
Madrid 6
Miami 6
Paris 6
Rio de Janeiro 6
Riverside 6
Riyadh 6
San Diego 6
San Salvador 6
The Bronx 6
Warsaw 6
Baghdad 5
Bakersfield 5
Figino 5
Florence 5
Istanbul 5
Jeddah 5
Kuala Lumpur 5
Maynooth 5
New Delhi 5
Quito 5
Toronto 5
Turin 5
Aurora 4
Belo Horizonte 4
Cairo 4
Charlotte 4
Chennai 4
Cherry Hill 4
Colorado Springs 4
Columbia 4
Denver 4
Dhaka 4
Dublin 4
Durban 4
Durham 4
Englewood 4
Guatemala City 4
Indianapolis 4
Kingston 4
Lahore 4
Longueuil 4
Milwaukee 4
Modena 4
Moreno Valley 4
Mumbai 4
Oklahoma City 4
Orlando 4
Padua 4
Totale 1.538
Salva come PNG Salva come JPEG
Nome #
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 69
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 67
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 64
Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations 52
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 51
Nipple sparing mastectomy as a risk‐reducing procedure for brca‐mutated patients 48
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 45
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 41
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 40
Global cancer control: responding to the growing burden, rising costs and inequalities in access 39
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 38
PARP Inhibitors for Breast Cancer Treatment 38
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer 37
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 32
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 32
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 32
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics 32
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 30
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 30
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer 29
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 29
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 28
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 26
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 25
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 25
A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report 25
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 25
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials 25
Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer 25
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 24
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 24
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 24
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 24
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer 24
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 24
Characterization of low HER2 expressions in de-novo metastatic breast cancer 24
Successes and limitations of targeted cancer therapy in breast cancer 23
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status 23
Tumori maligni del colon 23
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer 23
Dendritic cell-based vaccines : clinical applications in breast cancer 23
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 22
Neoadjuvant model for testing emerging targeted therapies in breast cancer 22
Adjuvant treatment of early male breast cancer 22
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 22
Over-using chemotherapy in the adjuvant setting 22
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 22
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 21
RNAi screens identify CHD4 as an essential gene in breast cancer growth 21
Pharmacological management of male breast cancer 21
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 21
Variant allele frequency: a decision-making tool in precision oncology? 21
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 20
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 20
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 20
[Exemestane in the treatment of breast carcinoma: recent findings] 20
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer 20
Immunotherapeutics for breast cancer 20
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 19
Immunotherapy of Breast Cancer 19
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 19
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence 19
Targeting brain metastases in breast cancer 19
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 19
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 19
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 19
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 19
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 18
Evolution of low HER2 expression between early and advanced-stage breast cancer 18
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 18
Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics 18
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 18
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 18
Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States 18
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 18
Tumor-stroma crosstalk: targeting stroma in breast cancer 18
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 18
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer 18
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 18
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 17
Targeting fibroblast growth factor receptor pathway in breast cancer 17
HER2-positive circulating tumor cells in breast cancer 17
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy 17
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management 17
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 17
Antibody–drug conjugates in solid tumors: a look into novel targets 17
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 17
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 16
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 16
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 16
The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario? 16
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 16
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective 16
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 15
Targeting the subtypes of breast cancer: Rethinking investigational drugs 15
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion 15
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 15
Best management of locally advanced inoperable breast cancer 15
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 15
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review 15
Totale 2.443
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 0 2 0 2 0
2022/202318 4 0 2 0 1 0 0 0 2 8 1 0
2023/202414 0 2 3 1 0 0 0 1 1 1 3 2
2024/202559 0 2 2 0 1 7 3 2 10 19 6 7
2025/20261.780 28 4 9 19 4 4 41 803 343 255 135 135
2026/20271.837 344 365 748 380 0 0 0 0 0 0 0 0
Totale 3.712